KR102346228B1 - 보체 활성의 조절 - Google Patents

보체 활성의 조절 Download PDF

Info

Publication number
KR102346228B1
KR102346228B1 KR1020197014115A KR20197014115A KR102346228B1 KR 102346228 B1 KR102346228 B1 KR 102346228B1 KR 1020197014115 A KR1020197014115 A KR 1020197014115A KR 20197014115 A KR20197014115 A KR 20197014115A KR 102346228 B1 KR102346228 B1 KR 102346228B1
Authority
KR
South Korea
Prior art keywords
polypeptide
polypeptides
complement
acid
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197014115A
Other languages
English (en)
Korean (ko)
Other versions
KR20190057420A (ko
Inventor
미쉘 데니스 호아르티
켁티 아쇼크 담나스카르
다니엘 엘바움
크리스트퍼 조지프슨
켈리 크로닌 라슨
중 마
나탄 에제키엘 님스
알론소 리카르도
캐슬린 세이브
궈-칭 탕
더글라스 에이. 트레코
자오린 왕
핑 예
훙 정
사라 재클린 펄머터
로버트 폴 해머
Original Assignee
라 파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54834568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102346228(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 라 파마슈티컬스 인코포레이티드 filed Critical 라 파마슈티컬스 인코포레이티드
Priority to KR1020217042686A priority Critical patent/KR102503319B1/ko
Publication of KR20190057420A publication Critical patent/KR20190057420A/ko
Application granted granted Critical
Publication of KR102346228B1 publication Critical patent/KR102346228B1/ko
Assigned to 유씨비 홀딩스 인코포레이티드 reassignment 유씨비 홀딩스 인코포레이티드 권리의 전부이전등록 Assignors: 라 파마슈티컬스 인코포레이티드
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197014115A 2014-06-12 2015-06-12 보체 활성의 조절 Active KR102346228B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217042686A KR102503319B1 (ko) 2014-06-12 2015-06-12 보체 활성의 조절

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201462011368P 2014-06-12 2014-06-12
US62/011,368 2014-06-12
US201462077460P 2014-11-10 2014-11-10
US62/077,460 2014-11-10
US201562108772P 2015-01-28 2015-01-28
US62/108,772 2015-01-28
PCT/US2015/035473 WO2015191951A2 (en) 2014-06-12 2015-06-12 Modulation of complement activity
KR1020167034788A KR101981532B1 (ko) 2014-06-12 2015-06-12 보체 활성의 조절

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167034788A Division KR101981532B1 (ko) 2014-06-12 2015-06-12 보체 활성의 조절

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217042686A Division KR102503319B1 (ko) 2014-06-12 2015-06-12 보체 활성의 조절

Publications (2)

Publication Number Publication Date
KR20190057420A KR20190057420A (ko) 2019-05-28
KR102346228B1 true KR102346228B1 (ko) 2022-01-04

Family

ID=54834568

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197014115A Active KR102346228B1 (ko) 2014-06-12 2015-06-12 보체 활성의 조절
KR1020217042686A Active KR102503319B1 (ko) 2014-06-12 2015-06-12 보체 활성의 조절
KR1020167034788A Active KR101981532B1 (ko) 2014-06-12 2015-06-12 보체 활성의 조절

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020217042686A Active KR102503319B1 (ko) 2014-06-12 2015-06-12 보체 활성의 조절
KR1020167034788A Active KR101981532B1 (ko) 2014-06-12 2015-06-12 보체 활성의 조절

Country Status (31)

Country Link
US (7) US10106579B2 (https=)
EP (4) EP4223317A3 (https=)
JP (4) JP6432954B2 (https=)
KR (3) KR102346228B1 (https=)
CN (3) CN106456701B (https=)
AP (1) AP2016009612A0 (https=)
AU (3) AU2015274482B2 (https=)
BR (3) BR112016029076B1 (https=)
CA (3) CA3241273A1 (https=)
CY (3) CY1122227T1 (https=)
DK (2) DK3154561T3 (https=)
ES (2) ES2895029T3 (https=)
FI (1) FIC20240015I1 (https=)
FR (1) FR24C1022I2 (https=)
HR (2) HRP20211561T8 (https=)
HU (3) HUE055931T2 (https=)
IL (3) IL249093B (https=)
LT (3) LT3628680T (https=)
MX (2) MX2016016449A (https=)
NL (1) NL301275I2 (https=)
NO (1) NO2024023I1 (https=)
NZ (1) NZ727420A (https=)
PL (2) PL3628680T3 (https=)
PT (2) PT3628680T (https=)
RS (2) RS59353B1 (https=)
RU (1) RU2670988C2 (https=)
SG (1) SG11201610222UA (https=)
SI (2) SI3154561T1 (https=)
SM (2) SMT202100588T1 (https=)
WO (1) WO2015191951A2 (https=)
ZA (3) ZA201706379B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015274482B2 (en) * 2014-06-12 2018-11-08 Ucb Holdings, Inc. Modulation of complement activity
EP3250230B9 (en) 2015-01-28 2022-02-23 RA Pharmaceuticals, Inc. Modulators of complement activity
ES2941640T3 (es) 2015-12-16 2023-05-24 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento
WO2017189837A1 (en) * 2016-04-29 2017-11-02 The Trustees Of The University Of Pennsylvania Protein kinase rna-like endoplasmic reticulum kinase (perk) inhibitors for prevention and/or treatment of lung injury and/or inflammation
MX2019006527A (es) 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
ES3013570T3 (en) 2018-06-21 2025-04-14 Ucb Holdings Inc Cyclic polypeptides for pcsk9 inhibition
ES3015132T3 (en) * 2018-06-21 2025-04-29 Ucb Holdings Inc Cyclic polypeptides for pcsk9 inhibition
US11530244B2 (en) 2018-06-21 2022-12-20 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
IL279363B2 (en) 2018-06-21 2025-12-01 Merck Sharp & Dohme Pcsk9 antagonist compounds
KR20210080390A (ko) * 2018-10-22 2021-06-30 라 파마슈티컬스 인코포레이티드 질루코플란을 이용한 신경 질환 치료
EP3934675A2 (en) 2019-03-08 2022-01-12 RA Pharmaceuticals, Inc. Zilucoplan as deep tissue penetrating c5 inhibitor
BR112021017820A2 (pt) * 2019-04-24 2022-02-08 Ra Pharmaceuticals Inc Composições e métodos para modulação da atividade de complemento
CN113966224A (zh) 2019-06-04 2022-01-21 Ra制药公司 采用补体抑制剂的炎性疾病治疗
EP4028126B1 (en) 2019-09-12 2025-02-26 RA Pharmaceuticals, Inc. Treatment of a neurological disease with complement inhibitors
US12577259B2 (en) 2019-12-20 2026-03-17 Merck Sharp & Dohme Llc PCSK9 antagonist compounds
JP6961860B1 (ja) 2019-12-26 2021-11-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 補体ｃ５の発現を抑制する二本鎖リボ核酸を含む医薬組成物
US11932705B2 (en) 2020-12-18 2024-03-19 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
WO2022177635A2 (en) * 2021-02-22 2022-08-25 Ra Pharmaceuticals, Inc. Compositions and methods for microbial disease treatment
MX2024003236A (es) 2021-09-15 2024-06-19 Viking Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
WO2023215294A1 (en) * 2022-05-02 2023-11-09 The Board Of Trustees Of The Leland Stanford Junior University Complement pathway inhibition for wound healing
US20260048028A1 (en) * 2022-08-16 2026-02-19 Ps Therapy, Inc. Methods of Use for Disulfiram and Metabolites Thereof
CN120981230A (zh) * 2023-03-31 2025-11-18 弗莱克斯塞思知识产权控股有限责任公司 杂芳基抗降解剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054623A1 (en) * 2004-12-17 2009-02-26 Neose Technologies, Inc. Lipo-Conjugation of Peptides
WO2013037267A1 (zh) * 2011-09-14 2013-03-21 深圳翰宇药业股份有限公司 利拉鲁肽变构体及其缀合物
US20130121917A1 (en) 2010-03-12 2013-05-16 Lawrence Berkeley National Laboratory Lipid-Peptide-Polymer Conjugates and Nanoparticles Thereof

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271068A (en) 1968-05-10 1981-06-02 Ciba-Geigy Corporation Process for the manufacture of cystine-containing peptides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4033940A (en) 1975-11-12 1977-07-05 Armour Pharmaceutical Company Cyclization of peptides
US4216141A (en) 1978-07-19 1980-08-05 The Salk Institute For Biological Studies Method for cyclization of peptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5371109A (en) 1986-07-01 1994-12-06 Drilletten Ab Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2641081A1 (https=) * 1988-12-23 1990-06-29 Medgenix Group
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK0494955T3 (da) 1989-10-05 1998-10-26 Optein Inc Cellefri syntese og isolering af hidtil ukendte gener og polypeptider
US5585353A (en) 1990-02-02 1996-12-17 The Rockefeller University Antibiotic peptides containing D-amino acids
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
CA2163620A1 (en) 1993-05-28 1994-12-08 Michael V. Doyle Method for selection of biologically active peptide sequences
DK0710243T3 (da) 1993-06-29 2000-10-16 Ferring Bv Syntese af cykliske peptider
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US5834318A (en) 1995-05-10 1998-11-10 Bayer Corporation Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US6720472B2 (en) 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
DE69730157T2 (de) 1996-10-17 2005-07-28 Mitsubishi Chemical Corp. Molekül, welches genotyp und phänotyp zusammenführt und dessen anwendungen
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
US5922680A (en) 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
DK1712623T3 (da) 1997-01-21 2012-02-06 Gen Hospital Corp Udvælgelse af proteiner ved anvendelse af RNA-proteinfusioner
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
EP0896001A1 (en) 1997-08-08 1999-02-10 Daicel Chemical Industries, Ltd. Method for preparing oxytocin antagoniste derivatives, intermediates for the preparation of oxytocin antagonist derivatives and method for preparing the intermediates
US6429301B1 (en) 1998-04-17 2002-08-06 Whitehead Institute For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
CN1313439C (zh) 1998-08-07 2007-05-02 艾米斯菲尔技术有限公司 用于送递活性剂的化合物和组合物
CA2343934A1 (en) * 1998-09-25 2000-04-06 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
WO2000021559A2 (en) 1998-10-09 2000-04-20 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
US6962781B1 (en) 2000-05-19 2005-11-08 Proteonova, Inc. In vitro evolution of nucleic acids and encoded polypeptide
US7244701B2 (en) 2000-06-16 2007-07-17 Zealand Phama A/S Diuretic peptide conjugate
WO2003074992A2 (en) * 2002-03-01 2003-09-12 Mds Proteomics Inc. Phosphorylated proteins and uses related thereto
WO2004035624A2 (en) * 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
EP2292259A3 (en) * 2002-11-15 2011-03-23 MUSC Foundation For Research Development Complement receptor 2 targeted complement modulators
KR20110059664A (ko) * 2003-05-05 2011-06-02 프로비오드룩 아게 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
US8329169B2 (en) 2003-05-15 2012-12-11 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
WO2005023866A2 (en) 2003-09-10 2005-03-17 Baxter International Inc. Peptides that inhibit complement activation
EP1706098A4 (en) 2003-11-26 2012-08-15 Supernus Pharmaceuticals Inc MICRO-LAYER SYSTEMS FOR THE TRANSPORT OF LIPOPHILES AND BZW. HYDROPHOBIC COMPOUNDS
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US20060027059A1 (en) 2004-08-09 2006-02-09 Chih-Ching Hsien Extendable handle device
DK1844337T3 (da) 2005-01-24 2013-09-30 Pepscan Systems Bv Bindingsforbindelser, immunogene forbindelser og peptidmimetika
CA2610502A1 (en) 2005-03-29 2006-10-05 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
CA2610340C (en) 2005-05-26 2016-02-16 Vernon Michael Holers Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
CA2609810C (en) 2005-06-06 2012-05-22 Camurus Ab Glp-1 analogue formulations
EP3299027A1 (en) 2005-11-04 2018-03-28 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
PL3167888T3 (pl) 2006-03-15 2024-08-26 Alexion Pharmaceuticals, Inc. Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza
EP1876183A1 (en) * 2006-07-04 2008-01-09 Technische Universität München Minimized small peptides with high affinity for factor VIII and factor VIII-like proteins
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
US7736860B2 (en) 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
WO2008109742A1 (en) 2007-03-06 2008-09-12 Novo Nordisk A/S Modulation of complement system activation for treatment of bleeding-related inflammation
JP2010521194A (ja) 2007-03-22 2010-06-24 ノバルティス アーゲー Ｃ５抗原およびその使用
US20100015139A1 (en) 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
US20080269318A1 (en) 2007-04-30 2008-10-30 Carmelo Romano Treatment of age-related macular degeneration using inhibitors of complement factor d
BRPI0812767A2 (pt) 2007-06-07 2014-12-02 Genentech Inc Anticorpos para c3b e métodos para prevenção e tratamento de distúrbios associados ao complemento
WO2009014633A1 (en) 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
AU2008308657A1 (en) 2007-10-02 2009-04-09 Potentia Pharmaceuticals, Inc. Sustained delivery of compstatin analogs from gels
WO2009067191A2 (en) 2007-11-16 2009-05-28 The General Hospital Corporation Methods and compositions for the treatment of hepatitis c virus (hcv) infection
EP2278987A4 (en) 2008-03-28 2012-08-22 Apellis Ag MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM
EP2324048A2 (en) 2008-07-30 2011-05-25 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof
PY09026846A (es) * 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
WO2010025510A1 (en) 2008-09-03 2010-03-11 Xenome Ltd Libraries of peptide conjugates and methods for making them
LT2894165T (lt) 2008-11-10 2023-03-10 Alexion Pharmaceuticals, Inc. Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
AU2009230735B1 (en) 2009-01-08 2010-01-21 Shane Ramodien Electronic equipment housing
CN102781471B (zh) 2009-10-16 2016-10-12 奥默罗斯公司 通过抑制masp-2依赖性补体活化治疗弥散性血管内凝血的方法
MX2012005151A (es) 2009-11-05 2012-08-23 Federico Ii University Of Naples Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular.
EP2512518A1 (en) 2009-12-16 2012-10-24 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
US9172511B2 (en) 2009-12-24 2015-10-27 Samsung Electronics Co., Ltd. Apparatus and method of communicating automatic repeat request (ARQ) feedback in a wireless communication network
WO2011106635A1 (en) 2010-02-25 2011-09-01 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
WO2011139343A2 (en) * 2010-04-28 2011-11-10 Wu Nian Amino acid linked peg-lipid conjugates
EP2563359A1 (en) 2010-04-30 2013-03-06 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
TW201241008A (en) * 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
CA2830065A1 (en) * 2011-03-16 2012-09-20 Amgen Inc. Potent and selective inhibitors of nav1.3 and nav1.7
KR101870915B1 (ko) 2011-04-08 2018-06-25 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
US20140296147A1 (en) * 2011-10-06 2014-10-02 The Medicines Company Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010
WO2013126006A1 (en) 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
US20130246083A1 (en) 2012-03-16 2013-09-19 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
EP2850095B1 (en) 2012-05-17 2019-10-09 RA Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
US20130345257A1 (en) 2012-06-26 2013-12-26 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
WO2014078622A1 (en) 2012-11-15 2014-05-22 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
US9700633B2 (en) * 2013-01-28 2017-07-11 Jenkem Technology Co., Ltd., Tianjin Branch Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
GB201301632D0 (en) * 2013-01-30 2013-03-13 Imp Innovations Complement System
US20140234275A1 (en) 2013-02-15 2014-08-21 Jason Williams Method for treating als via the increased production of factor h
WO2015025312A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
EP3119802B1 (en) 2014-03-20 2019-12-04 InflaRx GmbH Inhibitors of c5a for the treatment of viral pneumonia
AU2015274482B2 (en) 2014-06-12 2018-11-08 Ucb Holdings, Inc. Modulation of complement activity
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
US20160206580A1 (en) 2015-01-21 2016-07-21 Pacira Pharmaceuticals, Inc. Multivesicular liposome formulations of tranexamic acid
EP3250230B9 (en) * 2015-01-28 2022-02-23 RA Pharmaceuticals, Inc. Modulators of complement activity
WO2017035362A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
ES2941640T3 (es) 2015-12-16 2023-05-24 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento
MX2019006527A (es) 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
WO2019051436A1 (en) 2017-09-11 2019-03-14 Ra Pharmaceuticals, Inc. FORMULATIONS FOR THE ADMINISTRATION OF COMPOUNDS
BR112020010916A2 (pt) 2017-12-04 2020-11-17 Ra Pharmaceuticals, Inc moduladores da atividade do complemento
EP3934675A2 (en) 2019-03-08 2022-01-12 RA Pharmaceuticals, Inc. Zilucoplan as deep tissue penetrating c5 inhibitor
BR112021017820A2 (pt) 2019-04-24 2022-02-08 Ra Pharmaceuticals Inc Composições e métodos para modulação da atividade de complemento

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054623A1 (en) * 2004-12-17 2009-02-26 Neose Technologies, Inc. Lipo-Conjugation of Peptides
US20130121917A1 (en) 2010-03-12 2013-05-16 Lawrence Berkeley National Laboratory Lipid-Peptide-Polymer Conjugates and Nanoparticles Thereof
WO2013037267A1 (zh) * 2011-09-14 2013-03-21 深圳翰宇药业股份有限公司 利拉鲁肽变构体及其缀合物

Also Published As

Publication number Publication date
RU2670988C2 (ru) 2018-10-29
HUE045646T2 (hu) 2020-01-28
AU2019200828A1 (en) 2019-02-28
EP3154561A2 (en) 2017-04-19
CY1124595T1 (el) 2022-07-22
IL273746B (en) 2021-03-25
AU2015274482A1 (en) 2017-01-12
JP2020128417A (ja) 2020-08-27
RS59353B1 (sr) 2019-10-31
NZ736573A (en) 2024-03-22
NL301275I2 (nl) 2024-06-20
SMT202100588T1 (it) 2021-11-12
HRP20211561T8 (hr) 2022-03-04
EP3628680A1 (en) 2020-04-01
PT3628680T (pt) 2021-10-07
HUE055931T2 (hu) 2022-01-28
CN111187338B (zh) 2024-08-02
FIC20240015I1 (fi) 2024-05-28
WO2015191951A3 (en) 2016-03-03
EP3154561A4 (en) 2018-04-18
DK3154561T3 (da) 2019-10-07
CA3241273A1 (en) 2015-12-17
PL3628680T3 (pl) 2022-01-10
US10435438B2 (en) 2019-10-08
ES2750556T3 (es) 2020-03-26
KR20170003993A (ko) 2017-01-10
EP3628680B1 (en) 2021-09-08
US11014965B2 (en) 2021-05-25
DK3628680T3 (da) 2021-10-11
KR20190057420A (ko) 2019-05-28
ES2895029T3 (es) 2022-02-17
MX2021009309A (es) 2021-10-26
IL281264A (en) 2021-04-29
LT3154561T (lt) 2019-11-25
ZA202001859B (en) 2021-04-28
AU2019200828B2 (en) 2021-04-08
FR24C1022I2 (fr) 2025-05-23
KR102503319B1 (ko) 2023-02-28
AP2016009612A0 (en) 2016-12-31
JP6770043B2 (ja) 2020-10-14
LT3628680T (lt) 2021-11-25
HRP20211561T1 (hr) 2021-12-24
AU2021204313B2 (en) 2024-01-04
IL249093B (en) 2020-05-31
EP4223317A2 (en) 2023-08-09
EP3154561B1 (en) 2019-09-04
KR20220002727A (ko) 2022-01-06
CY2024015I2 (el) 2024-12-13
US20200123202A1 (en) 2020-04-23
IL273746A (en) 2020-05-31
AU2015274482B2 (en) 2018-11-08
FR24C1022I1 (fr) 2024-07-19
SG11201610222UA (en) 2017-01-27
BR122023024819A2 (pt) 2023-12-26
LTC3154561I2 (https=) 2025-11-10
BR112016029076A8 (pt) 2022-02-08
SI3154561T1 (sl) 2019-11-29
SMT201900568T1 (it) 2019-11-13
CY1122227T1 (el) 2020-11-25
IL249093A0 (en) 2017-01-31
EP4223317A3 (en) 2023-09-27
BR122021025449B1 (pt) 2024-02-15
CN106456701A (zh) 2017-02-22
US10562934B2 (en) 2020-02-18
RU2018136750A (ru) 2018-11-06
US11965040B2 (en) 2024-04-23
PL3154561T3 (pl) 2019-12-31
LTPA2024514I1 (https=) 2024-06-10
ZA201900497B (en) 2019-10-30
JP2019048834A (ja) 2019-03-28
CY2024015I1 (el) 2024-12-13
US20180371019A1 (en) 2018-12-27
HUS2400015I1 (hu) 2024-06-28
CN106456701B (zh) 2020-01-07
CA2949985A1 (en) 2015-12-17
JP7454545B2 (ja) 2024-03-22
RS62428B1 (sr) 2021-11-30
JP2022034057A (ja) 2022-03-02
NZ727420A (en) 2018-06-29
JP6432954B2 (ja) 2018-12-05
CA3174909A1 (en) 2015-12-17
US20170137468A1 (en) 2017-05-18
CN119236050A (zh) 2025-01-03
KR101981532B1 (ko) 2019-09-02
CN111187338A (zh) 2020-05-22
JP2017523232A (ja) 2017-08-17
MX2016016449A (es) 2017-08-24
US10106579B2 (en) 2018-10-23
US11535650B1 (en) 2022-12-27
US20210246167A1 (en) 2021-08-12
WO2015191951A2 (en) 2015-12-17
PT3154561T (pt) 2019-10-25
BR112016029076B1 (pt) 2024-02-15
JP7002597B2 (ja) 2022-02-04
BR112016029076A2 (pt) 2018-06-05
US20190119328A1 (en) 2019-04-25
RU2016147080A3 (https=) 2018-06-01
CA2949985C (en) 2023-10-17
US20200002380A1 (en) 2020-01-02
NO2024023I1 (no) 2024-05-24
US10208089B2 (en) 2019-02-19
NZ761610A (en) 2024-03-22
HRP20191763T1 (hr) 2019-12-27
RU2016147080A (ru) 2018-06-01
ZA201706379B (en) 2018-12-19
RU2018136750A3 (https=) 2021-10-19
AU2021204313A1 (en) 2021-07-22
SI3628680T1 (sl) 2021-12-31
IL281264B (en) 2022-05-01
EP3973994A1 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
US11535650B1 (en) Modulation of complement activity
US12239684B2 (en) Modulators of complement activity
RU2778514C2 (ru) Модуляция активности комплемента
HK40073624A (en) Modulators of complement activity
HK40072986A (en) Modulation of complement activity

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5

G19 Pte not granted

Free format text: ST27 STATUS EVENT CODE: A-4-4-G10-G19-TEX-PE0602 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0602 Decision to reject extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G19-tex-PE0602